#USA #Hayward #Lyme Disease #HealthBio #Inflamexa

HealthBio’s Bold Step in Lyme Disease Treatment

HealthBio, Inc., a biotechnology pioneer focused on innovative immune-reset therapies, has recently made headlines with the initiation of a multi-site randomized clinical trial to evaluate its lead therapeutic candidate, Inflamexa™, for individuals suffering from Post-Treatment Lyme Disease Syndrome (PTLDS). This significant trial, designated as HBT-002, aims to shed light on a persistent condition affecting many who have undergone treatment for Lyme disease.

A Closer Look at the Clinical Trial

The randomized, double-blind, placebo-controlled study plans to engage approximately 252 participants, sourced from at least six distinct sites across the United States. These sites are strategically chosen, being located in areas where Lyme disease is most prevalent. Selected participants will be assigned into two groups: one will receive the Inflamexa™ treatment, while the other will be administered matching placebos, both over a span of 12 weeks. The trial's primary objective is to evaluate fatigue levels at week 24, utilizing the modified Fatigue Severity Scale (FSS-11), which will help researchers understand the treatment's impact beyond the immediate intervention period.

In addition to the primary assessment, the study will also consider secondary evaluations including fatigue at week 12, quality of life metrics, general symptom burden, and both physical and mental health outcomes. Safety assessments will also be a crucial part of the study, ensuring the well-being of participants is monitored throughout the trial.

Linking Research to Treatment

This innovative trial is informed by previous research identifying a link between residual bacterial proteins and immune dysregulation in certain Lyme disease patients. Recent studies indicated the presence of Borrelia burgdorferi proteins in the monocytes of patients long after they completed antibiotic therapies, raising questions about the relationship between such remnants and chronic immune issues. Dr. Bruce K. Patterson, co-founder and CEO of HealthBio, noted that these insights provide a biological basis for exploring whether lingering bacterial components contribute to ongoing immune dysfunction.

Dr. Patterson emphasized the importance of connecting these immunological findings with structured clinical evaluation, highlighting HealthBio's commitment to advancing new treatment pathways for Lyme disease sufferers.

Understanding Lyme Disease and PTLDS

Post-Treatment Lyme Disease Syndrome can leave individuals grappling with debilitating symptoms even after antibiotic treatment. Patients often report persistent fatigue, joint pain, and neurological complications, which significantly obscure their daily lives. HealthBio aims to address these ongoing challenges with its Immune-reset therapy, directing particular attention towards the immune pathways that might underlie these chronic manifestations.

HealthBio’s Mission

Founded with the objective of developing diagnostic and therapeutic solutions for chronic inflammatory conditions, HealthBio continues to explore avenues that may significantly transform how we understand and treat diseases like Long COVID and Chronic Lyme Disease. By employing cutting-edge technologies, such as machine learning and AI-based diagnostics, the firm seeks to not only enhance treatment efficacy but also foster better diagnostic protocols in the field.

In closing, HealthBio's current efforts to evaluate Inflamexa™ can open new discourse regarding Lyme disease treatment, offering hope to countless individuals currently sidelined by PTLDS. The upcoming months will be critical in determining the efficacy of this innovative approach, with potential ramifications for the broader field of chronic infectious diseases.